Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

This phase 2 study assessed PF-3512676 plus erlotinib in patients with epidermal growth factor receptor-positive advanced non-small cell lung cancer after prior chemotherapy failure. Patients were randomized 1:1 to PF-3512676 (0.20 mg/kg injected subcutaneously once weekly) plus erlotinib (150 mg da...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Belani, Chandra P, Nemunaitis, John J, Chachoua, Abraham, Eisenberg, Peter D, Raez, Luiz E, Cuevas, J Daniel, Mather, Cecile B, Benner, Rebecca J, Meech, Sandra J
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Landes Bioscience 2013
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3742485/
https://ncbi.nlm.nih.gov/pubmed/23792641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24598
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg